Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of intravenous plitidepsin in advanced cancer
NL-OMON42098Recruiting
- Sponsor
- PharmaMar
- Start
- Mar 2015
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of plitidepsin in cancer, sponsored by PharmaMar. Primary endpoints: Mass balance of plitidepsin and Metabolite identification. Started Mar 2015; status: recruiting.
02
Drugs
plitidepsin
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON42098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42098.